Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 1 2Phase 2 1

Status

Withdrawn 1Recruiting 1Enrolling by invitation 1Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 5OTHER 3

Study Type

Interventional 5

Sponsor

Cancer Type

Genitourinary 1Gastrointestinal 1CNS 1

Conditions

Carcinoma, Non-Small-Cell Lung 501Neoplasms 304Breast Neoplasms 298Colorectal Neoplasms 230Neoplasm Metastasis 196Prostatic Neoplasms 175Ovarian Neoplasms 173Lung Neoplasms 160Multiple Myeloma 159Recurrence 134Melanoma 125Pancreatic Neoplasms 116Squamous Cell Carcinoma of Head and Neck 105Stomach Neoplasms 103Leukemia, Myeloid, Acute 102Endometrial Neoplasms 102Small Cell Lung Carcinoma 89Leukemia, Lymphocytic, Chronic, B-Cell 87Triple Negative Breast Neoplasms 85Lymphoma, Non-Hodgkin 85Carcinoma, Renal Cell 83Carcinoma, Hepatocellular 79Urinary Bladder Neoplasms 77Lymphoma, Large B-Cell, Diffuse 74Lymphoma, Follicular 68Advanced Solid Tumors 66Parkinson Disease 4, Autosomal Dominant Lewy Body 62Lymphoma 62Glioblastoma 59Head and Neck Neoplasms 57

Interventions

pembrolizumab 1liposomal doxorubicin 1Tumor Necrosis Factor-alpha 11-dodecylpyridoxal 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
INDUSTRY × Adenoviridae Infections × 90 days × Clear all
NCT07544589 2026-05-29

A Phase 1 Study Evaluating DISP-10 in Participants With Advanced Gastrointestinal Cancers

Dispatch Biotherapeutics

Phase 1 Recruiting
66 enrolled
Gastrointestinal

Adenocarcinoma Of Esophagus, Adenoviridae Infections, Gastrointestinal Neoplasms, Colorectal Neoplasms

NCT05271318 2026-05-05

PROTA

TILT Biotherapeutics Ltd.

Phase 1/2 Active not recruiting
29 enrolled

Adenoviridae Infections

NCT02143804 2026-04-02

exBOND

CG Oncology, Inc.

Phase 2 Withdrawn
Genitourinary

Adenoviridae Infections, Urinary Bladder Neoplasms

NCT06763965 2026-03-23

Evaluating the Safety and Efficacy of BioTTT001 in Patients With Recurrent/Progressive High-grade Glioma.

Beijing Bio-Targeting Therapeutics Technology Co., Ltd

Phase 1/2 Enrolling by invitation
30 enrolled
CNS

Adenoviridae Infections, Glioma

NCT04695327 2026-03-06

TUNIMO

TILT Biotherapeutics Ltd.

Phase 1 Completed
32 enrolled

Adenoviridae Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡